To validate that the effect of FOXA1 deacetylation upon HER2/HER3 activation is less likely dependent on ER, we evaluated the expression of genes associated with worse prognosis in breast cancer upon heregulin and fulvestrant treatment for 3 h. This evidence concerns the gene FOXA1 and breast carcinoma.